To determine the extent to which gadolinium chelate is found in nonhuman primate fetal tissues and amniotic fluid at 19-45 hours after intravenous injection of a weight-appropriate maternal dose of the contrast agent gadoteridol.
Gravid Japanese macaques (n = 14) were maintained as approved by the institutional animal care and utilization committee. In the 3rd trimester of pregnancy, the macaques were injected with gadoteridol (0.1 mmol per kilogram of maternal weight). Fetuses were delivered by means of cesarean section within 24 hours of maternal injection (range, 19-21 hours; n = 11) or 45 hours after injection (n = 3). Gadolinium chelate levels in the placenta, fetal tissues, and amniotic fluid were obtained by using inductively coupled plasma mass spectrometry. The Wilcoxon rank sum test was used for quantitative comparisons.
Results:
Gadoteridol was present in the fetoplacental circulation at much lower quantities than in the mother. At both time points, the distribution of gadolinium chelate in the fetus was comparable to that expected in an adult. The highest concentration of the injected dose (ID) was found in the fetal kidney (0.0161% ID per gram in the 19-21-hour group). The majority of the in utero gadolinium chelate was found in the amniotic fluid and the placenta (mean, 0.1361% ID per organ 6 0.076 [standard deviation] and 0.0939% ID per organ 6 0.0494, respectively). Data acquired 45 hours after injection showed a significant decrease in the gadolinium chelate concentration in amniotic fluid compared with that in the 19-21-hour group (from 0.0017% to 0.0007% ID per gram; P = .01).
Conclusion:
Amounts of gadolinium chelate in the fetal tissues and amniotic fluid were minimal compared with the maternal ID. This may impact future clinical studies on the safety of gadolinium contrast agent use in pregnancy.
T raditionally, fetal and placental imaging has been centered on ultrasonography (US), which is considered safe in pregnancy and can provide excellent anatomic resolution of the developing fetus and placenta. Similar to US in nongravid patients, limitations include patient-dependent resolution and lack of ability to obtain functional data. Magnetic resonance (MR) imaging allows non-contrast material-enhanced imaging of the fetus and placenta for detailed evaluation of the anatomy and is being studied for use in advanced fetal applications, including gated fetal cardiac imaging and the assessment of placental function and fetal structural brain development (1) (2) (3) . When imaging the morbidly adherent placenta with MR imaging, gadolinium chelate use is controversial but may increase specificity and be valuable for assessing the degree of placental invasion (4) (5) (6) (7) (8) . With the growing use of MR imaging for various disease processes, protocols that would otherwise utilize contrast material are often altered for the incidentally pregnant patient (9, 10) .
Implication for Patient Care
n Among animal models, placental organization in nonhuman primates is most similar to that of the human placenta; we report the gadolinium chelate levels in nonhuman primate fetuses after maternal gadoteridol injection, and therefore our results may have implications for the safety of contrast-enhanced MR imaging during pregnancy.
Advances in Knowledge
n After intravenous injection of gadoteridol into a pregnant nonhuman primate, there is evidence of transplacental passage of gadolinium chelate into the fetal circulation, although the majority of the contrast agent dose remains in the maternal circulation.
n The highest concentration of the injected dose (ID) was found in the fetal kidney (0.0161% ID per gram in the 19-21-hour group).
n The majority of the in utero gadolinium chelate was found in the amniotic fluid and the placenta (0.1361% ID per organ 6 0.076 [standard deviation] and 0.0939% ID per organ 6 0.0494, respectively).
n Minimal gadolinium chelate is detected in the fetal tissues at 21 and 45 hours after maternal contrast agent injection. 
Funding:
This research was supported by the National Institutes of Health (grants R21-HD-076265, R24-DK-090964, P51-OD-011092, S10RR025512-01, and P30 CA69533).
Conflicts of interest are listed at the end of this article.
Gadolinium (Gd

3+
) chelates are traditionally avoided in pregnancy because of potential safety concerns for the fetus and are listed as a Class C drug by the U.S. Food and Drug Administration. In general, Class C drugs should be used only if the potential benefits outweigh the potential risks to the fetus (11, 12) . The European Society of Urogenital Radiology Contrast Media Safety Committee guidelines state that the highest-risk gadolinium contrast media are contraindicated in pregnant women, while the intermediate-and lowest-risk gadolinium contrast media may be given to pregnant women in the lowest dose required to provide essential diagnostic information (12) .
Understanding the physiology of gadolinium chelate distribution in the fetus is the basis for assessing safety in pregnancy. In animal models, including mice, rats, and rabbits, gadoliniumbased contrast medium has been injected intravenously into the pregnant animal at high doses, showing that gadolinium chelate reaches the fetal circulation (13) (14) (15) . Gadolinium-based contrast material crosses the placenta into the fetal circulation, to be excreted by the fetal kidneys into the amniotic fluid (13, 15, 16) . In nonhuman primates, gadolinium chelate has been found to enhance the placenta and has subsequently been seen in the fetal bladder on serial MR image acquisitions (16) . However, to our knowledge, the quantitative levels of Gd 3+ in the primate fetus have not previously been measured.
The effect of gadolinium-based contrast material on the developing fetus is unknown. Defining the levels of Gd 3+ in the fetal environment after maternal intravenous injection would be the first step in evaluating any potential effect on the fetus. The aim of this study was to determine the amount of Gd 3+ in the nonhuman primate fetus and amniotic fluid at 19-21 and 45 hours after administration of a maternal intravenous dose of 0.1 mmol per kilogram of body weight of a gadolinium-based contrast agent, gadoteridol (ProHance; Bracco Diagnostics, Princeton, NJ).
Materials and Methods
Animals
All protocols were prospectively approved by the Institutional Animal Care and Utilization Committee of the Oregon National Primate Research Center, and guidelines for humane animal care were followed.
Study animals were part of an existing study of the use of dynamic contrast-enhanced MR imaging to evaluate primate placental vascular organization (3, 17) . The dynamic contrast-enhanced MR imaging study is part of an ongoing nonhuman primate model developed to demonstrate that consumption of a
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Western-style diet, independent of maternal obesity and/or diabetes, causes broad developmental issues in the fetus and that placental dysfunction, abnormal uterine hemodynamics, and placental inflammation are important contributors to these developmental abnormalities (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . Japanese macaques (n = 9) were maintained on a high-fat diet (36% calories from fat, Test Diet, 5 L0P; Purina Mills, Richmond, Ind) supplemented with calorically dense treats for 4-7 years. The composition of the high-fat diet represents a typical Western-style diet in regard to the saturated fat content. Control animals (n = 5) were fed standard chow, which provides 14% calories from fat. All animals were socially housed in indoor-outdoor pens with one or two male macaques and three to 11 female macaques per diet-determined cohort and had ad libitum access to food and water. Animals were allowed to breed naturally, and pregnancies were identified by means of routine US. Term pregnancy for macaques is approximately 175 days. Delivery at gestational day 130 (equivalent to the 3rd trimester) was planned for all pregnant macaques undergoing dynamic contrastenhanced MR imaging. For the purposes of this study, two time points after maternal dosing were used. In the 19-21-hour group, dynamic contrast-enhanced MR imaging was performed at gestational day 129 (n = 11, with three control animals and eight animals receiving the high-fat diet). In the 45-hour group, dynamic contrast-enhanced MR imaging was performed at gestational day 128 (n = 3, with two control animals and one animal receiving the high-fat diet). A total of 14 pregnant macaques and their fetuses were evaluated for this study. All 14 animals underwent dynamic contrastenhanced MR imaging for the purposes of the primary existing study protocol for placental evaluation (3) .
After an overnight fast, animals were initially sedated with 3-5 mg/kg intramuscular Telazol in preparation for the MR imaging protocol, which included gadoteridol injection. Once intubated, the macaque was maintained in a state of general anesthesia with 1%-2% isoflurane gas. Flumazenil (0.01 mg/kg) was administered intravenously to reverse the effects of Telazol (3).
Gadolinium Chelate Injection
Gadoteridol (ProHance) was injected intravenously into the cephalic vein of the sedated gravid macaque during dynamic contrast-enhanced MR imaging (study and data reported separately [3] ). Gadoteridol is the chelate formed between Gd 3+ and 10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetate. The dose of gadoteridol was based on a standard clinical dose of 0.1 mmol per kilogram of maternal weight. Maternal weight ranged from 8.1 to 17.8 kg, with a mean of 12.6 kg. Animals underwent dynamic contrast-enhanced MR imaging series of T1-weighted three-dimensional gradient-recalled-echo sequences in a Siemens (Erlangen, Germany) whole-body 3.0-T MR imaging system, with a CP transmit 15-channel receive radiofrequency coil (QED, Cleveland, Ohio) (3).
Tissue Collection
Fetuses were delivered by cesarean section and were taken immediately to the pathology unit for full necropsy. Placenta, amniotic fluid, and fetal tissues were harvested, dissected, and snap frozen in liquid nitrogen. Fetal tissue samples included brain, liver, and kidney samples from all 14 fetuses. Fetal skin samples were obtained from three fetuses in the 19-21-hour group, and bone samples (from the femur or calvarium) were obtained from three fetuses in the 19-21-hour group. Skin and bone samples were not obtained from all fetuses because these tissues were not harvested initially as part of the existing placental dynamic contrast-enhanced MR imaging study protocol. Maternal plasma samples were collected, processed, and stored at −80°C for later analysis.
In Vivo Gd 3+ Analysis
Gd 3+ concentrations (in millimoles per liter) were obtained from a representative macaque MR imaging study of the gravid uterus after maternal intravenous gadoteridol injection. In vivo measurements were obtained for 6 minutes after injection, by using regions of interest (ROIs) placed on the maternal kidney, maternal muscle, and the placenta and a three-dimensional ROI over the fetus (Fig 1) . Relative enhancement was converted to Gd 3+ concentration by using the full nonlinear signal equation described by Schabel and Parker (28) , with field-dependent relaxivity values and preinjection values of T10 determined by using the variable flip angle method with flip angles of 3° and 25° (29, 30) .
Tissue Gd 3+ Assay
Inductively coupled plasma mass spectrometry was performed to assess the amount of Gd 3+ in the fetal tissues. The analysis was performed in the Elemental Analysis Core at Oregon Health and Science University by using an Agilent 77003 device equipped with an ASX 250 autosampler. For the analysis, tissue or fluid samples of approximately 100 mg were weighed and transferred into acid-treated borosilicate tubes and were digested with 1 mL concentrated HNO 3 (trace metal grade, Fisher Scientific, Pittsburgh, Pa) at 90°C for 2 
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Oh et al Note that inductively coupled plasma mass spectrometry is capable only of registering the presence of the Gd 3+ ion; it is not possible to use it to distinguish between the chelated and dechelated forms of the ion. Accordingly, we use the term "Gd 3+ " to refer to the presence of the gadolinium ion detected in the inductively coupled plasma mass spectrometry analysis, whether in the chelated state or in the dechelated form. The limit of detection for the samples was determined from calibration standards to be 0.6 parts per trillion, which resulted in a limit of detection of about 3.8 3 10
211 percent injected dose (ID) per gram. 
Statistical Analysis
The quantitative levels of Gd 3+ in the fetal tissue were expressed as percentages ID per gram or as percentages ID per organ. Percentage ID per gram reflects the percentage of the maternal ID found per gram of tissue. Percentage ID per organ represents the percentage of the injected maternal dose found in the organ of interest. For these calculations in amniotic fluid, the amniotic fluid volumes were estimated to be 80 mL, on the basis of limited normative values for the macaque and on our unpublished experience with
Gd
3+ Analysis
The in vivo Gd 3+ concentrations in the maternal kidney, the maternal muscle, the placenta, and the entire fetus after maternal intravenous administration of gadoteridol indicated that the level of gadoteridol reaching the fetus was far lower than the level administered to the mother (Fig 2) . As shown, the highest (95th percentile) of signal intensity measurements of Gd 3+ in the fetus were still overall lower than the median concentrations of Gd 3+ in the maternal kidney and muscle and in the placenta.
Quantitative amounts of Gd 3+ in fetal tissue from the inductively coupled plasma mass spectrometry assay are provided in Tables 1 and 2. Table 3 shows comparative Gd 3+ levels at the two time points. The median levels of Gd 3+ in the amniotic fluid in the 45-hour group were significantly lower than those in the 19-21-hour group (P = .01). Amounts of gadolinium chelate were then expressed as percentages ID per gram of tissue and percentages ID per organ to assess the proportion of the maternal ID found in the fetal tissues (Tables 4, 5 ). In both the 19-21-hour group and the 45-hour group, the relative concentration (percentage ID per gram) was highest in the fetal kidneys (Fig 3) . The highest total amount of Gd 3+ was found in the amniotic fluid and placenta (percentage ID per organ) (Fig 4) 
Discussion
We chose to utilize the contrast agent gadoteridol because of its inherent stability, which results from binding the gadolinium ion in a nonionic macrocyclic chelate (HP-DO3A). This stability would be expected to translate into minimal free ion disassociation and subsequently minimize the toxic effect of gadolinium. The Gd 3+ chelates used for imaging vary in their thermodynamic and kinetic stability, with some much less likely to demetallate and release the toxic Gd 3+ ion. The European Medicines Agency has categorized the various gadolinium agents as "highest risk," "intermediate risk," and "lowest risk" on the basis of the stability of the binding chelates (33) . Because
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3+
-based contrast agents have been shown to enhance the placenta (3), and transplacental transfer of these agents occurs (3, 13, 15, 16) . We theorized that likely only a small amount of the contrast agent reaches the fetal circulation; however, the percentage of the total dose of gadoteridol that actually crosses into the fetal circulation is unknown in primates. To gauge the relative in vivo amounts of contrast agent reaching the fetus compared with the maternal circulation immediately after intravenous gadoteridol injection, we estimated the amount of Gd 3+ in the maternal kidney, maternal muscle, placenta, and fetus by measuring ROIs over these areas on dynamic MR images. As shown, the amount of gadoteridol reaching the fetus is far lower than that administered to the mother.
Japanese macaques have a developmental ontogeny that is similar to that in humans, including placental function (34, 35) . Like humans, nonhuman primates have a hemochorial placenta with organization into multiple cotyledons (36, 37) . Maternal blood flow is delivered to the placenta via the uterine arteries, which branch into spiral arteries and perfuse the intervillous space of the cotyledons of the placenta (38) . Other researchers (13) (14) (15) 39) have reported biodistribution in mice, rats, and rabbits; however, hemochorial placental organization is absent in these animals, which lack the nutrient exchange mechanism provided by the intervillous space.
Once gadoteridol is injected intravenously and enters the intervillous space of the placenta, the agent must transport through the trophoblast layers, which surround the fetal capillaries, into the fetal endothelial cells. Gaining access to the fetal vasculature, the gadoteridol then enters the fetal circulation via the umbilical vein, which delivers blood to the fetal heart after shunting it past the fetal liver via the ductus venosus. Subsequently, the agent is excreted by the fetal kidneys into the amniotic fluid 3+ concentration in maternal kidneys, maternal muscle, placenta, and the fetus versus time immediately after intravenous administration of 0.1 mmol/kg gadoteridol to the mother. The fetal concentration of Gd 3+ is reported at the 95th percentile of the signal intensity measurements obtained from the three-dimensional ROI over the fetus, as compared with the median (substantially higher) concentrations in the maternal tissues. These data were obtained from a single representative gravid macaque after contrast agent injection. At time point 0.0, there is apparent detection of gadolinium chelate in the maternal kidney. This is likely an artifact due to respiratory motion. Shaded areas = standard deviations of the concentrations. * For the skin and the femur, there was one animal in the control group and two animals in the high-fat diet group. P values were not calculated because of the small sample size.
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of amniotic fluid volume results from fetal lung excretion as well (40) . However, there are pathways through which gadoteridol may return to the maternal circulation. First, some of the agent can be sent back to the placenta via the umbilical arteries, which carry blood away from the fetus. Second, there can be (13, 16) . Recirculation occurs when the gadoteridol is excreted into the amniotic fluid as urine, which the fetus regularly swallows during gestation (40, 41) . Solutes such as gadoteridol would presumably then be absorbed through the fetal gastrointestinal tract back into the fetal bloodstream. A small component intramembranous transport across the placental amnion into fetal microvessels at the fetal surface of the placenta (42) . Gaining access to the fetal circulation through this mechanism of bulk flow, the agent can potentially cross back to the maternal circulation through the placenta. Prolonged in vivo residence increases the risk of disassociation of the Gd 3+ ion from its chelate (39, 43, 44) . Liberated Gd 3+ ion is toxic and could be detrimental to fetal development. Rapid clearance is therefore highly advantageous in ensuring that the chances of substantial dechelated Gd 3+ accumulation within the fetoplacental circulation are minimized.
We quantified the amounts of Gd 3+ in the nonhuman primate fetus, placenta, and amniotic fluid. Results of other studies (13) (14) (15) 39) have shown biodistribution in gravid mice, rats, and rabbits after injection of variable doses of gadolinium contrast agents. In animal and human studies involving MR imaging after maternal injection, Gd
3+
-based contrast agents have been shown to enhance the placenta (3), and transplacental transfer of these agents occurs (3, 13, 15, 16) . In our nonhuman primate model, the majority of Gd 3+ was found in the amniotic fluid and placenta. This is consistent with perfusion of the placenta via the uterine arteries, passing a portion of the maternal dose of gadolinium-based contrast agents to the placenta. Once within the placental vascular system, Gd 3+ in the fetal tissues and amniotic fluid reflects transplacental entrance into fetal circulation.
Gadoteridol is known to be excreted exclusively though the kidneys (39) . As the contrast agent is filtered from the blood, the agent rapidly accumulates in the kidneys. Elevated levels of Gd 3+ persist as excretion continues in adult rats after the injection of a weight-appropriate dose, and detectable levels of Gd This suggests that the low levels of Gd 3+ after injection are not simply the result of gadoteridol being excluded from the fetal circulation but that Gd 3+ is also actively eliminated from the fetus.
Relatively little Gd 3+ was observed in the fetal liver or femur tissues. Excretion through the hepatobiliary system would be expected to give rise to elevated levels of Gd 3+ in the liver; however, both the concentration and the total Gd 3+ level in the liver were found to be low-much lower than in adult rodents (39) . Furthermore, the presence of minimal Gd 3+ in the liver and femur strongly indicates that gadoteridol is excreted intact. If the Gd 3+ ion dissociates from the chelate, it rapidly precipitates into particulate matter and is deposited in the reticuloendothelial system (the liver) and, eventually, in calcium-containing structures (39, 45, 46) . The Gd 3+ ion has comparable chemical properties to the Ca 2+ ion and therefore in vivo has a high affinity for the phosphate ion. On the basis of results of rodent studies, dechelated Gd 3+ deposits in the skeletal system within 1 day after injection (39, 45, 46) . The minimal levels of Gd 3+ observed in the fetal liver and femur in our study confirm negligible free ion deposition, as also observed in adult rodents (39, 45, 46) .
We quantified Gd 3+ in nonhuman primate fetal tissues after a weight-appropriate maternal dose and showed that the fate of gadoteridol entering the fetal circulation is very similar to that in the adult animal. As with human adults, there is no indication that the agent crosses the blood-brain barrier-the minute amounts detected are likely due to contamination from vascular structures. Trace amounts of the maternal dose were present in the highest-yield fetal tissues outside the kidneys (liver, bone, skin), similar to findings in adult animal models. No direct assessment of gadoteridol accumulation in maternal tissues was performed as part of our study because the necessary tissue samples were not available. Instead, Gd 3+ levels in maternal plasma at the time of delivery were assessed and showed extremely low levels of Gd 3+ ([2.5 6 1.3] 3 10 25 percent ID per gram). These data are consistent with those in a previous report by Tweedle et al (39) of Gd 3+ levels in adult rodents 24 hours after administration. Of note, the limit of detection for inductively coupled plasma mass spectrometry is far lower than the limit of detection for scintillation (3.8 3 10
211 percent ID per gram vs 0.004% ID per gram 6 0.001, respectively), which was the method used for quantification in that study (39) . Additional studies could be performed to correlate the fetoplacental tissue levels of gadoteridol with the maternal tissue levels, to assess if maternal variations can alter fetal exposure to the agent. 
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Currently, opportunities for the use of Gd 3+ -based contrast agents in the evaluation of the placenta include MR imaging of placental perfusion and enhancement in the setting of insufficiency or intrauterine growth restriction and, potentially, MR imaging of the morbidly adherent placenta. In the incidentally pregnant patient with abdominal pain, contrast media may be useful in the evaluation of acute appendicitis, pyelonephritis, inflammatory bowel disease, and neoplasm staging (8, 10, 47) . In certain scenarios, the trace amount of residual Gd 3+ in the fetoplacental circulation found in our study may be less clinically important than the diagnostic limitations existing when imaging without contrast material.
Practical application: Our study of the gravid nonhuman primate shows minimal residual Gd 3+ in the fetal tissues and amniotic fluid by 21 hours after maternal intravenous injection of weight-based clinical doses of gadoteridol in the 3rd trimester, with the suggestion of continued excretion. Although there will likely be continued debate as to whether gadolinium chelate administration during pregnancy is justified for diagnostic imaging, our study provides information that may alleviate some uncertainty regarding the potential for Gd 3+ toxicity to the fetus after maternal dosing. 
